老齡化黃斑部病變（AMD）市場規模、佔有率、成長分析：產品類型、分子類型、核准類型、AMD類型、最終用戶和地區 - 產業預測，2026-2033年

預計到 2024 年，老齡化黃斑部病變(AMD) 市場規模將達到 112.9 億美元，到 2025 年將成長至 125.1 億美元，到 2033 年將成長至 284.2 億美元，在預測期（2026-2033 年）內，複合年成長率為 10.8%。

老齡化黃斑部病變（AMD）是一種進行性眼科疾病，主要影響老年人，涉及視網膜中央區域，逐漸導致視力喪失。此病主要分為乾性AMD和濕性AMD兩種類型，其中乾性AMD較常見。雖然改變生活方式和補充維生素可以有效控制乾性AMD，但濕性AMD需要更具侵入性的治療，通常是注射抗VEGF藥物來抑制異常血管增生。由於此病患病率不斷上升以及人口老化導致人們對藥物的依賴性日益增強，全球AMD治療市場正在不斷擴大。因此，尋求AMD治療的患者人數不斷成長，預示著旨在改善患者生活品質的創新治療方法和預防措施的市場需求將持續成長。

老齡化黃斑部病變（AMD）市場成長要素

全球老齡化黃斑部病變（AMD）市場的成長主要受老年人口不斷成長的推動，老年人更容易患上這種疾病。隨著預期壽命的延長，越來越多的人面臨與AMD相關的風險因素。這一趨勢導致人們對有效治療方法的需求不斷成長，這些方案旨在控制病情並預防視力喪失。由於醫療服務提供者和患者都希望應對這種與老齡化相關的視力障礙帶來的影響，因此迫切需要找到解決AMD挑戰的方案，最終推動了市場的創新和擴張。

老齡化黃斑部病變市場的阻礙因素

由於某些地區篩檢和診斷流程不完善，老齡化黃斑部病變）市場面臨嚴峻挑戰，不僅對患者的健康結果產生負面影響，也導致治療延誤。此外，人們對現有診斷工具的認知度較低，也阻礙了市場擴張，導致患者延遲接受治療。這種延誤不僅限制了現有療法的潛在療效，也加重了疾病的整體負擔。如果無法改善及時篩檢的可近性，並加深對診斷方案的了解，市場將無法充分發揮其潛力，也難以為AMD患者提供最佳的治療方案。

老齡化黃斑部病變（AMD）市場趨勢

老齡化黃斑部病變(AMD) 市場已顯著轉向長效治療方法，尤其是長效抗 VEGF 療法。這一趨勢旨在透過減少疾病管理所需的注射次數，提高患者的依從性。這些創新最大限度地減輕了治療負擔，改善了患者體驗和治療效果，並推動了 AMD 市場的整體成長。這些進步不僅解決了傳統治療方法面臨的挑戰，也預示著治療方向將向更有效率、更人性化的治療方法轉變，最終將塑造 AMD 治療的未來。

目錄

介紹

• 調查目標
• 定義
• 市場覆蓋範圍

調查方法

• 資訊收集
• 二手和一手資料資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

前景
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場動態
  • 促進要素
  • 機會
  • 抑制因素
  • 任務
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 技術分析
• 定價分析
• 價值鏈分析
• 供應鏈分析
• 專利分析
• 客戶和購買標準分析
• 案例研究分析

按產品分類的老齡化黃斑部病變治療市場

• Ailea 和 Ailea HD
• Lucentis
• 瓦維茲莫
• 奇福布雷
• 其他產品

按分子分類的老齡化黃斑部病變藥物市場

• 阿黃曲普
• 法瑞西單抗
• 雷珠單抗
• 培塞他可普蘭
• 其他分子

按核准類型分類的老齡化黃斑部病變治療市場

• 生物製藥
• 生物相似藥

按AMD類型分類的老齡化黃斑部病變治療市場

• 濕性AMD
• 乾性酸性礦山排水

按最終用戶分類的老齡化黃斑部病變治療市場

• 醫院
• 長期照護機構
• 專業醫療中心
• 其他

按地區分類的老齡化黃斑部病變治療藥物市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲（MEA）
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市佔率（2025 年）

主要企業簡介

• Biogen（US）
• Formycon AG（Germany）
• Coherus Biosciences（US）
• Biocon（India）
• Outlook Therapeutics, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Intas Pharmaceuticals Ltd.（India）
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.（China）
• Ocular Therapeutix, Inc.（US）
• Opthea Limited（Australia）
• Kodiak Sciences Inc.（US）
• Bio-Thera（China）
• Amgen Inc.（US）
• Alvotech（Iceland）
• Stealth Biotherapeutics Inc.（US）
• Alteogen Inc.（South Korea）
• Ocumension Therapeutics（China）
• Innovent（China）
• Regeneron Pharmaceuticals, Inc.（US）
• Shanghai Henlius Biotech, Inc.（China）

Age-related Macular Degeneration Market size was valued at USD 11.29 Billion in 2024 and is poised to grow from USD 12.51 Billion in 2025 to USD 28.42 Billion by 2033, growing at a CAGR of 10.8% during the forecast period (2026-2033).

Age-related macular degeneration (AMD) is a progressive eye condition affecting the central retina, leading to gradual vision loss, primarily in older adults. The condition is classified into two major types: dry and wet AMD, with dry being the more prevalent. While lifestyle modifications and vitamin supplements may help manage dry AMD, wet AMD requires more invasive treatments, typically involving anti-VEGF injections to inhibit the growth of abnormal blood vessels. The global AMD market is expanding, driven by the increasing prevalence of this condition among the aging population and their reliance on medication. Consequently, the rise in patients seeking treatment for AMD suggests a growing market for therapeutic innovations and preventative measures aimed at improving the quality of life for those affected.

Top-down and bottom-up approaches were used to estimate and validate the size of the Age-related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Age-related Macular Degeneration Market Segments Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Age-related Macular Degeneration Market

The growth of the global age-related macular degeneration (AMD) market is significantly influenced by the rising population of older adults who are more vulnerable to this condition. As life expectancy increases, more individuals face heightened exposure to the risk factors associated with AMD. This trend has resulted in an increased demand for effective therapies and treatments aimed at managing the disease and preventing vision loss. The urgency for solutions to address the challenges posed by AMD ultimately drives innovation and expansion within the market, as both healthcare providers and patients seek to confront the impacts of this age-related vision impairment.

Restraints in the Age-related Macular Degeneration Market

The Age-related Macular Degeneration market faces significant challenges due to inadequate screening and diagnostic processes in certain regions, which adversely affect health outcomes and contribute to treatment delays. Furthermore, a lack of awareness regarding available diagnostic tools hampers market expansion, leading to individuals receiving late interventions. This delay not only limits the potential effectiveness of existing therapies but also exacerbates the overall burden of the disease. Without improved access to timely screenings and a greater understanding of diagnostic options, the market struggles to realize its full potential and provide optimal patient care for those affected by AMD.

Market Trends of the Age-related Macular Degeneration Market

The Age-related Macular Degeneration (AMD) market is witnessing a notable shift towards long-acting therapies, particularly extended-duration anti-VEGF treatments. This trend addresses a critical need for improved patient compliance by reducing the frequency of injections required to manage the condition. By minimizing treatment burdens, these innovations enhance patient experience and outcomes, driving the overall growth of the AMD market. Such advancements not only respond to the challenges faced by previous therapies but also signify a broader movement toward more efficient and patient-friendly treatment modalities, ultimately shaping the future landscape of AMD management.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Patent Analysis
• Customer & Buying Criteria Analysis
• Case Study Analysis

Age-Related Macular Degeneration Drugs Market by Product

• Market Overview
• Eylea & Eylea HD
• Lucentis
• Vabysmo
• Syfovre
• Other Products

Age-Related Macular Degeneration Drugs Market by Molecule

• Market Overview
• Aflibercept
• Faricimab
• Ranibizumab
• Pegcetacoplan
• Other Molecules

Age-Related Macular Degeneration Drugs Market by Approval Type

• Market Overview
• Biologics
• Biosimilars

Age-Related Macular Degeneration Drugs Market by Type of AMD

• Market Overview
• Wet AMD
• Dry AMD

Age-Related Macular Degeneration Drugs Market by End User

• Market Overview
• Hospitals
• Long-Term Care Facilities
• Specialty Centers
• Others

Age-Related Macular Degeneration Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2025

Key Company Profiles

• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Formycon AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coherus Biosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intas Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Thera (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alvotech (Iceland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stealth Biotherapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alteogen Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocumension Therapeutics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Henlius Biotech, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments